AI-aided Optical Coherence Tomography for the Detection of Basal Cell Carcinoma

Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Apr 4, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to detect basal cell carcinoma (BCC), which is the most common type of skin cancer. Traditionally, doctors confirm BCC by taking a small sample of skin through a procedure called a punch biopsy, which can be invasive. This study is exploring the use of a non-invasive technique called Optical Coherence Tomography (OCT) that can scan the skin without needing to take a sample. The trial is also testing how artificial intelligence (AI) can help doctors using OCT by pointing out areas that may be concerning and suggesting possible diagnoses. The goal is to see if this technology can make it easier and more accurate for doctors to identify BCC.

To participate in this study, you need to be at least 18 years old and have already had both an OCT scan and a punch biopsy for a skin lesion that may be BCC. Unfortunately, if you are unable to sign the consent form, you won't be eligible. If you join the trial, you can expect to be part of an important effort to improve skin cancer detection methods, which may eventually lead to less invasive options for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients (18+ years)
• • Patient underwent OCT scan and punch biopsy for an equivocal BCC lesion
• Exclusion Criteria:
• • - Patient unable to sign informed consent